Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
MARTINEZ-CARPIO, P.A.; BONAFONTE-MARQUEZ, E.; HEREDIA-GARCIA, C.D. y BONAFONTE-ROYO, S.. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.10, pp.579-587. ISSN 0365-6691.
Purpose: Systematic review on efficacy and safety of intravitreal bevacizumab (IVB) in the treatment of neovascular glaucoma (NVG). All original papers published in Medline (prior to August 2008) were included. Methods: Search and selection of information on the internet and in Medline, validated by Kappa Index (K). Statistical and clinical study of the results in the selected articles on a one by one basis. Results: 26 original papers analyzed the efficacy and safety of the procedure in case reports and short series of cases (127 eyes). The efficacy calculated in the sample was 68.7% and the recurrence rate was 18.6% in 4.2 months of follow-up. All studies were after 2006 and none of them was a clinical randomized controlled assay. Ophthalmic complications were under 0.78% and no systemic complications were found. Conclusions: The use of bevacizumab demonstrates that intravitreal injections may be effective and useful to manipulate growth factors in the anterior chamber. IVB could serve as a first line treatment for NVG. Clinical trials are needed to confirm these results before its use is authorized.
Palabras clave : Bevacizumab; avastin; intravitreal injection; neovascular glaucoma; rubeosis iridis; laser photocoagulation; growth factors; systematic review.